KR102662725B1 - Pd-l1 발현에 기반한 종양 및 면역 세포 영상화 - Google Patents

Pd-l1 발현에 기반한 종양 및 면역 세포 영상화 Download PDF

Info

Publication number
KR102662725B1
KR102662725B1 KR1020197021481A KR20197021481A KR102662725B1 KR 102662725 B1 KR102662725 B1 KR 102662725B1 KR 1020197021481 A KR1020197021481 A KR 1020197021481A KR 20197021481 A KR20197021481 A KR 20197021481A KR 102662725 B1 KR102662725 B1 KR 102662725B1
Authority
KR
South Korea
Prior art keywords
cancer
delete delete
tumor
compound
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197021481A
Other languages
English (en)
Korean (ko)
Other versions
KR20190102018A (ko
Inventor
스리다 니마가다
마틴 쥐. 폼퍼
사미트 채터지
보이치에흐 쥐. 레스니악
디라지 쿠마르
Original Assignee
더 존스 홉킨스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 존스 홉킨스 유니버시티 filed Critical 더 존스 홉킨스 유니버시티
Priority to KR1020247003223A priority Critical patent/KR20240023665A/ko
Publication of KR20190102018A publication Critical patent/KR20190102018A/ko
Application granted granted Critical
Publication of KR102662725B1 publication Critical patent/KR102662725B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/225—Microparticles, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acoustics & Sound (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020197021481A 2016-12-23 2017-12-21 Pd-l1 발현에 기반한 종양 및 면역 세포 영상화 Active KR102662725B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247003223A KR20240023665A (ko) 2016-12-23 2017-12-21 Pd-l1 발현에 기반한 종양 및 면역 세포 영상화

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662438575P 2016-12-23 2016-12-23
US62/438,575 2016-12-23
US201762519534P 2017-06-14 2017-06-14
US62/519,534 2017-06-14
PCT/US2017/068025 WO2018119313A1 (en) 2016-12-23 2017-12-21 Tumor and immune cell imaging based on pd-l1 expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247003223A Division KR20240023665A (ko) 2016-12-23 2017-12-21 Pd-l1 발현에 기반한 종양 및 면역 세포 영상화

Publications (2)

Publication Number Publication Date
KR20190102018A KR20190102018A (ko) 2019-09-02
KR102662725B1 true KR102662725B1 (ko) 2024-04-30

Family

ID=62627749

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197021481A Active KR102662725B1 (ko) 2016-12-23 2017-12-21 Pd-l1 발현에 기반한 종양 및 면역 세포 영상화
KR1020247003223A Ceased KR20240023665A (ko) 2016-12-23 2017-12-21 Pd-l1 발현에 기반한 종양 및 면역 세포 영상화

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247003223A Ceased KR20240023665A (ko) 2016-12-23 2017-12-21 Pd-l1 발현에 기반한 종양 및 면역 세포 영상화

Country Status (11)

Country Link
US (1) US11607466B2 (https=)
EP (1) EP3558395A4 (https=)
JP (3) JP7784103B2 (https=)
KR (2) KR102662725B1 (https=)
CN (1) CN110366432A (https=)
AU (1) AU2017382282B9 (https=)
BR (1) BR112019012986A2 (https=)
CA (1) CA3048229A1 (https=)
IL (1) IL267572B2 (https=)
MX (1) MX2019007615A (https=)
WO (1) WO2018119313A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN109512798B (zh) * 2019-01-15 2022-05-13 南京从一医药科技有限公司 一种用于抗肿瘤免疫治疗的药物组合物纳米体系
CN111662270A (zh) * 2019-03-05 2020-09-15 中国医学科学院药物研究所 碘同位素标记苄苯醚衍生物、及其制法和药物组合物与用途
CN110898234B (zh) * 2019-12-25 2020-12-22 河南大学 一种二维铋纳米复合材料及其制备方法和应用
TWI833056B (zh) 2019-12-31 2024-02-21 財團法人工業技術研究院 核酸藥物複合體以及其用途
CN112067586B (zh) * 2020-06-24 2021-08-03 江南大学 一种基于荧光淬灭拉曼增强的前列腺特异性抗原双信号光谱分析方法
CA3188677A1 (en) * 2020-08-07 2022-02-10 Sridhar Nimmagadda Imaging and targeting programmed death ligand-1 (pd-li) expression
DE102020130954A1 (de) 2020-11-23 2022-05-25 Universität Duisburg-Essen Markierungspartikel für Raman-Streuung und/oder Fluoreszenz-Strahlung
CN114853851B (zh) * 2021-02-04 2023-08-15 南方医科大学南方医院 靶向pd-l1多肽探针及其在制备pet显像剂中的应用
CN113341023B (zh) * 2021-06-30 2022-12-23 大连医科大学附属第一医院 一种基于液质联用的血清二氨基庚二酸的检测试剂盒及检测方法与应用
WO2023014999A1 (en) * 2021-08-06 2023-02-09 The Johns Hopkins University Aluminum fluoride radiosynthesis of [18f]dk222
CN115364247A (zh) * 2021-09-15 2022-11-22 中国人民解放军海军军医大学第一附属医院 一种靶向显影剂、制备方法及其应用
CN114010655B (zh) * 2021-11-02 2023-02-03 安徽医科大学第一附属医院 一种识别和降解前列腺癌细胞表面的pd-l1的金纳米星及其制备方法和应用
CN114569745A (zh) * 2022-03-18 2022-06-03 哈尔滨医科大学 一种靶向pd-l1的多肽pet分子成像探针及其制备方法与应用
AU2024344671A1 (en) * 2023-09-20 2026-03-26 Trimt Gmbh Functionalized peptides for in-vivo addressing of pd-l1 expression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016039749A1 (en) 2014-09-11 2016-03-17 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542371A (en) * 2003-03-19 2008-10-31 Universitatsspital Basel Radiolabeled conjugates based on substance P and the uses thereof
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2012074840A2 (en) * 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
US20140316255A1 (en) * 2011-09-02 2014-10-23 Ellis Garai Raman Imaging Devices and Methods of Molecular Imaging
US11268958B2 (en) * 2012-09-14 2022-03-08 The Johns Hopkins University Bacteria-specific labeled substrtates as imaging biomarkers to diagnose, locate, and monitor infections
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
ES2981335T3 (es) * 2014-11-25 2024-10-08 Bristol Myers Squibb Co Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
HUE054306T2 (hu) * 2016-05-19 2021-08-30 Bristol Myers Squibb Co Immunmodulátorok PET-képalkotás számára
CN107869033B (zh) * 2016-09-26 2020-10-02 青岛胶南海尔洗衣机有限公司 一种干衣机用正反转风扇及干衣机

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016039749A1 (en) 2014-09-11 2016-03-17 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Wojciech G. Lesniak 외. PD-L1 Detection in Tumors Using [64Cu]Atezolizumab with PET. Bioconjugate Chem. 2016, Vol. 27, pp. 2103-2110

Also Published As

Publication number Publication date
EP3558395A4 (en) 2020-08-12
KR20240023665A (ko) 2024-02-22
IL267572A (en) 2019-08-29
US11607466B2 (en) 2023-03-21
EP3558395A1 (en) 2019-10-30
AU2017382282B9 (en) 2025-02-13
JP2020514278A (ja) 2020-05-21
JP2025118743A (ja) 2025-08-13
JP7784103B2 (ja) 2025-12-11
BR112019012986A2 (pt) 2019-12-03
IL267572B1 (en) 2024-10-01
WO2018119313A1 (en) 2018-06-28
CN110366432A (zh) 2019-10-22
JP7680759B2 (ja) 2025-05-21
US20190314531A1 (en) 2019-10-17
CA3048229A1 (en) 2018-06-28
JP2023052071A (ja) 2023-04-11
IL267572B2 (en) 2025-02-01
AU2017382282A1 (en) 2019-07-11
AU2017382282B2 (en) 2025-01-30
MX2019007615A (es) 2019-11-05
KR20190102018A (ko) 2019-09-02

Similar Documents

Publication Publication Date Title
KR102662725B1 (ko) Pd-l1 발현에 기반한 종양 및 면역 세포 영상화
Wester et al. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging
Miao et al. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein
US12465660B2 (en) Compositions and methods for cancer imaging and radiotherapy
KR102665275B1 (ko) 신규 항인간 CEACAM5 항체 Fab 프래그먼트
Färber et al. Therapeutic radiopharmaceuticals targeting integrin αvβ6
Kuil et al. Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression
Donnelly et al. The discovery and evaluation of [18F] BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement
Sharma et al. CD38‐Specific Gallium‐68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET
US20230271923A1 (en) Imaging and targeting programmed death ligand-1 (pd-li) expression
US12285502B2 (en) HER3 peptides for imaging and radiotherapy
Privat et al. Development of an Immuno-SPECT/Fluorescent Bimodal Tracer Targeting Human or Murine PD-L1 on Preclinical Models
US11795197B2 (en) Peptide compositions for immuno-oncology molecular imaging and targeted drug delivery
Schreck et al. Radiometal Complexes as Pharmacokinetic Modifiers: A Potent 68Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonist Based on the Macrocyclic Metal Chelator NODIA-Me
EA052886B1 (ru) Визуализация опухолевых и иммунных клеток на основе экспрессии pd-l1
Dilworth et al. The radiopharmaceutical chemistry of Gallium (III) and Indium (III) for SPECT imaging
Wang et al. Influence of chelator and near-infrared dye labeling on biocharacteristics of dual-labeled trastuzumab-based imaging agents
WO2025072791A2 (en) Miniproteins, conjugates & uses thereof
Woodard et al. Molecular Imaging of CXCR4 Receptor Expression in Tumors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601